Cannabis-Related Disorders and Toxic Effects: Insights from Gorelick’s Review

David A. Gorelick’s December 2023 review, “Cannabis-Related Disorders and Toxic Effects,” examined adverse physical and mental health effects of cannabis use and the need for better treatments. It remains useful background, but intoxication, withdrawal, cannabis use disorder, and persistent psychiatric symptoms are different clinical problems. They should not be collapsed into a single diagnosis or a home-treatment checklist.

The guidance below places that review in context using additional public-health and clinical sources. It also corrects an important medication distinction: dronabinol, nabilone, and nabiximols are not interchangeable names for CBD.

Intoxication Can Affect Judgment, Coordination, and Physical Health

THC can alter perception and impair memory and cognition. Taking too much may cause marked anxiety, panic, confusion, rapid heart rate, nausea, vomiting, or hallucinations. The California Department of Public Health identifies these as possible signs of cannabis poisoning. The amount consumed, product strength, route, tolerance, and other substances all matter when assessing a reaction.

Cannabis also impairs skills needed for driving, including reaction time, coordination, and decision-making. Comparisons with alcohol do not establish that driving after cannabis is safe. Arrange another way home and avoid combining intoxicants.

The American Heart Association describes cardiovascular safety concerns, including increased heart rate and signals of adverse cardiac outcomes, while noting limitations in the research. New chest symptoms or fainting should not simply be dismissed as an expected high.

When a Reaction Needs Medical Attention

For a concerning exposure in the United States, call Poison Control at 1-800-222-1222. If someone collapses, has a seizure, has trouble breathing, or cannot be awakened, call 911 immediately. Do not induce vomiting. Keep the product packaging available for the clinician or poison specialist if possible.

Severe agitation, hallucinations, or disorientation also warrant prompt assessment. A clinician may need to consider other drugs or medical and psychiatric causes rather than assuming cannabis explains everything. Sedatives and antipsychotic medicines mentioned in clinical literature require professional assessment and monitoring; they are not instructions to use someone else’s prescription or treat a serious reaction at home.

Withdrawal and Cannabis Use Disorder Are Distinct

Withdrawal can follow stopping or substantially reducing heavy or prolonged use. Symptoms may include irritability, anxiety, reduced appetite, sleep disruption, disturbing dreams, and physical discomfort. A clinical review of withdrawal management describes a typical onset within 24–48 hours, a peak around days 2–6, and symptoms that can persist for three weeks or longer in heavy users. Individual courses vary.

Withdrawal does not, by itself, establish cannabis use disorder. That diagnosis involves a problematic pattern of use with clinically significant impairment or distress. Difficulty cutting down and continued use despite problems are reasons to seek assessment rather than reasons for blame.

NIDA describes behavioral approaches including cognitive behavioral therapy, motivational enhancement therapy, and contingency management. These can help people change use patterns and build skills for recovery. There are no FDA-approved medicines specifically for cannabis use disorder or medically assisted cannabis withdrawal; a 2026 NIH research notice reiterates the unmet need for an approved CUD medication.

Drug studies should not be read as evidence that retail CBD treats withdrawal. Dronabinol is THC, nabilone is a synthetic THC analogue, and nabiximols contains THC and CBD. The withdrawal literature discusses investigational and symptom-focused approaches, with supportive counseling and education as first-line care. Treatment planning should also account for other substance use and mental health conditions.

Persistent Symptoms Need Their Own Assessment

Anxiety, sleep disturbance, psychotic symptoms, or confusion should not automatically be labeled “subacute” because they last longer than 24 hours. Their relationship to intoxication, withdrawal, an underlying disorder, and other exposures needs clinical evaluation. A broad percentage from selected research populations cannot tell an individual whether persistent psychosis will develop.

If symptoms continue after the immediate effects have passed, discuss them with a healthcare professional. Recovery support may need to address both cannabis use and an accompanying mental health problem.

Repeated Vomiting and Pregnancy Require Particular Attention

Cannabinoid hyperemesis syndrome (CHS) involves recurrent episodes of severe nausea and vomiting associated with prolonged, frequent cannabis use. The American Gastroenterological Association warns about dehydration, kidney injury, and electrolyte disturbances. Persistent vomiting needs medical care rather than further cannabis use to try to control nausea.

The AGA’s diagnostic guidance emphasizes symptom resolution with sustained abstinence. Other causes of vomiting must still be considered. Stopping cannabis and obtaining support for doing so are central to evaluating and managing suspected CHS.

The CDC recommends avoiding cannabis during pregnancy. People using it for nausea, sleep, pain, or anxiety should discuss alternatives with their prenatal clinician. The relevant concern is prenatal exposure, not simply whether someone would otherwise be described as a long-term user.